Physician profile
Jun Levine
NPI 1487971602
$10,687.27
in general payments reported to CMS, 2019-2025
17 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,750 · 2020: $645 · 2021: $468 · 2022: $862 · 2023: $1,830 · 2024: $1,796 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594 · Travel and Lodging: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.46 |
| Travel and Lodging | $1,367.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,814.40 | 2021-2025 | Ligasure, Signia, Endo Gia Ultra |
| Intuitive Surgical, INC. | $3,575.20 | 2019-2024 | |
| Covidien Lp | $1,110.79 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $733.73 | 2019-2022 | |
| Baxter Healthcare | $537.07 | 2019-2023 | Peri-Strips Dry |
| Novo Nordisk INC | $251.19 | 2023-2025 | Wegovy |
| Tela Bio, INC. | $151.21 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $124.74 | 2019 | |
| Intra-Sana Laboratories | $106.53 | 2021-2023 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Avanos Medical | $82.78 | 2019 | |
| Teleflex LLC | $43.98 | 2023 | Titan Sgs Standard Gastric Stapler |
| Currax Pharmaceuticals LLC | $31.12 | 2023-2024 | Contrave |
| Organogenesis INC. | $30.95 | 2022 | |
| Davol INC. | $29.00 | 2019 | |
| Standard Bariatrics, INC. | $25.22 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.27 | 2024 | Jardiance, Zepbound |
| Pacira Pharmaceuticals Incorporated | $17.09 | 2023 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.